Funding Goal
Amount Pledged
Days Left

Company Overview

  • Stocosil is a pharmaceutical company delivering next generation products that treat the double-threat of hypertension and high cholesterol.

    Stocosil strikes at the heart of cardiovascular disease with their lead drug product, Kybiqo —a dual-drug pill that simultaneously treats hypertension and high cholesterol, that may reduce risk by a dramatic 45%. Kybiqo is a fixed dose combination of olmesartan medoxomil and rosuvastatin calcium which currently does not exist in the United States.

    In addition to Kybiqo, Stocosil has a strong pipeline of products that will tap into a large global market and multi-billion dollar revenue potential.

    Stocosil boasts an impressive management team possessing significant experience in drug development.

(200 symbols max)

(256 symbols max)